Klaus Ueberla

Title: Klaus Ueberla: Innovator in Respiratory Syncytial Virus Research

Introduction

Klaus Ueberla is a notable inventor based in Sprockhoevel, Germany. He has made significant contributions to the field of virology, particularly in the development of vaccines against respiratory syncytial virus (RSV). His work has implications for public health, especially in protecting vulnerable populations from viral infections.

Latest Patents

Ueberla holds a patent for the RSV F-protein and its use. The patent describes a nucleic acid molecule that codes for the F-protein of RSV or a fragment thereof. This invention focuses on the expression of codon-optimized variants of the nucleic acid molecule in a human cell environment. It also includes vectors and compositions comprising these nucleic acid molecules, which can be utilized as vaccines and polypeptides coded by the nucleic acid molecules. The method for the production of these components is also outlined in the patent.

Career Highlights

Throughout his career, Klaus Ueberla has worked with several prominent organizations. He has been associated with Pevion Biotech AG, where he contributed to innovative biotechnological solutions. Additionally, he has worked at Ruhr-Universität Bochum, furthering his research in the field of virology and vaccine development.

Collaborations

Ueberla has collaborated with various professionals in his field, including Thomas Grunwald. Their joint efforts have likely advanced the understanding and treatment of viral infections.

Conclusion

Klaus Ueberla's work in the development of vaccines against respiratory syncytial virus showcases his dedication to improving public health through innovative research. His contributions are vital in the ongoing fight against viral diseases.